At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

WESTLAKE VILLAGE, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing...

The recent take down of market leadership wasn’t what we were looking for – and my trading list now has more of a variety of names given the selloff in growth areas. Our Top Pick is Arcutis Biotherapeutics Inc. (ARQT), says <strong>Mike Cintolo</strong>, editor of Cabot Momentum Trader.

Larry Todd Edwards proposed selling 60,376 common shares through Merrill Lynch, with an approximate sale date of October 20, 2026.

Key TakeawaysArcutis shares rose 12% after Guggenheim raised its price target to $44 from $38 and kept its Buy rating, citing “growing conviction” about 2027. It’s the second bullish call in a week, after Cantor Fitzgerald started coverage on Thursday with an Overweight rating and a $48 target.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.